Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Oncologie Completes $80 Million B Round for US-China Oncology Development

publication date: Jun 10, 2019

Oncologie, a Boston-Shanghai biopharma, raised $80 million in a Series B funding to support its biomarker driven in-licensing of mid-stage oncology assets. The round was led by existing investors Nan Fung Life Sciences and Pivotal BioVentures China, and joined by new investors including Panacea Venture Healthcare and Korea Investment Partners. Oncologie is developing three candidates for cancer including its lead molecule, bavituximab, an immune-modulatory mAb that targets phosphatidylserine, a phospholipid that inhibits the ability of immune cells to recognize and fight tumors. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital